Journal: Materials Today Bio

Article Title: 4D-printed Fe3O4-PLLA scaffolds modulate osteoimmune microenvironment for oral bone repair

doi: 10.1016/j.mtbio.2025.102691

Figure Lengend Snippet: In vitro immunomodulatory properties of PLLA, Fe 3 O 4 -PLLA, CSMA/Fe 3 O 4 -PLLA, NG-CSMA/Fe 3 O 4 -PLLA scaffolds. a-b) 3 days of co-culture of RAW 264.7 with PLLA, Fe 3 O 4 -PLLA, CSMA/Fe 3 O 4 -PLLA, and NG-CSMA/Fe 3 O 4 -PLLA scaffolds, flow cytometry was performed to analyze M1, M2 markers CD86 and CD206. c) mRNA levels of TNF-α, IL-1β, Arg-1, and CD206 by qRT-PCR; d) Immunofluorescence images of M1 (iNOS) and M2 (Arg-1) macrophage markers; and e) quantitative analysis of fluorescence intensity. n = 3. (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001).

Article Snippet: After 3 days, cells were harvested, blocked, and stained with PE-anti-CD206 and CL647- anti -CD86 antibodies (Proteintech, China).

Techniques: In Vitro, Co-Culture Assay, Flow Cytometry, Quantitative RT-PCR, Immunofluorescence, Fluorescence

Journal: Journal of translational medicine

Article Title: SIRPB1 regulates inflammatory factor expression in the glioma microenvironment via SYK: functional and bioinformatics insights.

doi: 10.1186/s12967-024-05149-z

Figure Lengend Snippet: Fig. 2 A, B SIRPB1 expression in astrocytoma and glioblastoma cell clusters. C Correlation of SIRPB1 with immune cell infiltration. D Association between macrophage infiltration and SIRPB1; Wilcoxon and Spearman tests. E SIRPB1 and macrophage correlation in TCGA-GBM via TIMER2.0. F Kaplan–Meier curves for OS of TCGA-GBMLGG with ICR-high. G Co-localization of SIRPB1 with TMEM119, CD86, and CD163 in glioma. H SIRPB1 levels in glioma and monocyte lines from CCLE. I SIRPB1 expression in human and mouse glioma, microglia, and monocyte lines

Article Snippet: The induced THP-1 macrophages were collected, Fc receptors were blocked by human Fc Receptor Blocking Solution (Maokangbio), stained with FITC Anti-Mouse/ Human CD11b Antibody (Elabscience, clone:M1/70), 7-AAD (Elabscience), APC Anti-Human CD206 Antibody (Elabscience, clone:15–2) and PE Anti-Human CD86 Antibody (Elabscience, clone:BU63), and detected and analyzed by Beckman cytoflex flow cytometry.

Techniques: Expressing

Journal: Journal of translational medicine

Article Title: SIRPB1 regulates inflammatory factor expression in the glioma microenvironment via SYK: functional and bioinformatics insights.

doi: 10.1186/s12967-024-05149-z

Figure Lengend Snippet: Fig. 4 SIRPB1 Knockout and Macrophage Polarization. A T7E1 assay results. WT wild-type, NC negative control, PC positive control. B SIRPB1 and FLAG-cas9 expression in THP-1 lines. C Sanger sequencing of SIRPB1WT and SIRPB1KO. D Protein expression post-M1/M2 treatments. E mRNA levels of M1/M2 markers (*P < 0.05, **P < 0.01, ***P < 0.001, Dunnett’s test). F Flow cytometry of CD11b, CD86, CD206 in THP-1 lines

Article Snippet: The induced THP-1 macrophages were collected, Fc receptors were blocked by human Fc Receptor Blocking Solution (Maokangbio), stained with FITC Anti-Mouse/ Human CD11b Antibody (Elabscience, clone:M1/70), 7-AAD (Elabscience), APC Anti-Human CD206 Antibody (Elabscience, clone:15–2) and PE Anti-Human CD86 Antibody (Elabscience, clone:BU63), and detected and analyzed by Beckman cytoflex flow cytometry.

Techniques: Knock-Out, Negative Control, Positive Control, Expressing, Sequencing, Flow Cytometry

Journal: Frontiers in Immunology

Article Title: Paeonol Interferes With Quorum-Sensing in Pseudomonas aeruginosa and Modulates Inflammatory Responses In Vitro and In Vivo

doi: 10.3389/fimmu.2022.896874

Figure Lengend Snippet: Paeonol changed the Polarization of Macrophages infected with PAO1 (MOI = 25:1). Control (A) , PAO1 (B) The data in “PAO1+Pae 32 μg/mL” (D) , “PAO1+Pae 64 μg/mL” (E) , and “PAO1+Pae 128 μg/mL” (F) indicated that Paeonol reversed the upregulated the biomarker of CD86 of RAW264.7 cells infected with PAO1 (C) . The cell polarization was distinguished by Flow cytometry. All data were expressed as means ± SD (n=3). * P < 0.05 or ** P < 0.01 vs PAO1 group.

Article Snippet: The cells were stained with F4/80 (Elabscience, E-AB-F0995C), CD86 (Elabscience, E-AB-F0994E), and CD206 (Elabscience, E-AB-F1135D) fluorescently labeled antibody, then detected by a flow cytometer (Beckman coulter, CytoFLEX) and analyzed by the Flowjo software.

Techniques: Infection, Control, Biomarker Discovery, Flow Cytometry

Journal: Acta Histochemica et Cytochemica

Article Title: Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor

doi: 10.1267/ahc.21-00075

Figure Lengend Snippet: Procedures of automatic immunostaning for CD80, CD86 and PD-L1 in this study

Article Snippet: Rabbit monoclonal antibodies for CD80 (ab269587, clone EPR1157(2)), CD86 (ab134120, clone EP1158-37) and PD-L1 (SP142) were purchased from Abcam (Cambridge, UK), Abcam and Roche Diagnostics Japan (Tokyo, Japan), respectively.

Techniques: Polymer, Amplification, Blocking Assay

Journal: Acta Histochemica et Cytochemica

Article Title: Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor

doi: 10.1267/ahc.21-00075

Figure Lengend Snippet: Immunohistochemistry for CD80, CD86 and PD-L1 in NSCLC. A : CD80 was immunolocalized in tumor-infiltrating immune cells (IC) adjacent to tumor cells (TC). B : CD68 immunoreactivity in the same area as A. A great majority of CD80-positive cells is CD68-positive macrophages. C : Some CD80-positive cells (upper panel) were considered as CD3-positive T lymphocytes (lower panel) in this area. D : CD86 immunoreactivity was mainly detected in macrophages in IC. E : PD-L1 immunoreactivity was mainly detected in macrophages in IC. Same area as A. F : PD-L1 immunoreactivity was detected in TC, but not in IC, in this area. Bar = 50 μm, respectively.

Article Snippet: Rabbit monoclonal antibodies for CD80 (ab269587, clone EPR1157(2)), CD86 (ab134120, clone EP1158-37) and PD-L1 (SP142) were purchased from Abcam (Cambridge, UK), Abcam and Roche Diagnostics Japan (Tokyo, Japan), respectively.

Techniques: Immunohistochemistry

Journal: Acta Histochemica et Cytochemica

Article Title: Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor

doi: 10.1267/ahc.21-00075

Figure Lengend Snippet: Association between CD80 and clinicopathological parameters in 75 lung carcinomas

Article Snippet: Rabbit monoclonal antibodies for CD80 (ab269587, clone EPR1157(2)), CD86 (ab134120, clone EP1158-37) and PD-L1 (SP142) were purchased from Abcam (Cambridge, UK), Abcam and Roche Diagnostics Japan (Tokyo, Japan), respectively.

Techniques:

Journal: Acta Histochemica et Cytochemica

Article Title: Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor

doi: 10.1267/ahc.21-00075

Figure Lengend Snippet: Association between CD86 and clinicopathological parameters in 75 lung carcinomas

Article Snippet: Rabbit monoclonal antibodies for CD80 (ab269587, clone EPR1157(2)), CD86 (ab134120, clone EP1158-37) and PD-L1 (SP142) were purchased from Abcam (Cambridge, UK), Abcam and Roche Diagnostics Japan (Tokyo, Japan), respectively.

Techniques:

Journal: Acta Histochemica et Cytochemica

Article Title: Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor

doi: 10.1267/ahc.21-00075

Figure Lengend Snippet: Overall survival of 75 NSCLC patients according to CD80, CD86, PD-L1 (IC), PD-L1 (TC) and combined CD80/PD-L1 (IC) status. The solid line shows their high group, and the dashed line shows their low group in A–D. P -values < 0.05 were considered significant and shown in bold.

Article Snippet: Rabbit monoclonal antibodies for CD80 (ab269587, clone EPR1157(2)), CD86 (ab134120, clone EP1158-37) and PD-L1 (SP142) were purchased from Abcam (Cambridge, UK), Abcam and Roche Diagnostics Japan (Tokyo, Japan), respectively.

Techniques:

Journal: Acta Histochemica et Cytochemica

Article Title: Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor

doi: 10.1267/ahc.21-00075

Figure Lengend Snippet: Association between mRNA expression of CD80, CD86 and PD-L1 and overall survival in lung cancer patients using Kaplan-Meir Plotter for lung cancer. The mRNA expression level in each case was classified into two groups (high (red line) and low (black line)) by the median value (n = 1,925).

Article Snippet: Rabbit monoclonal antibodies for CD80 (ab269587, clone EPR1157(2)), CD86 (ab134120, clone EP1158-37) and PD-L1 (SP142) were purchased from Abcam (Cambridge, UK), Abcam and Roche Diagnostics Japan (Tokyo, Japan), respectively.

Techniques: Expressing

Journal: Acta Histochemica et Cytochemica

Article Title: Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor

doi: 10.1267/ahc.21-00075

Figure Lengend Snippet: Univariate and multivariate analyses of overall survival in 75 lung cancer patients

Article Snippet: Rabbit monoclonal antibodies for CD80 (ab269587, clone EPR1157(2)), CD86 (ab134120, clone EP1158-37) and PD-L1 (SP142) were purchased from Abcam (Cambridge, UK), Abcam and Roche Diagnostics Japan (Tokyo, Japan), respectively.

Techniques:

Journal: Proceedings of the National Academy of Sciences of the United States of America

Article Title: EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer.

doi: 10.1073/pnas.2220276120

Figure Lengend Snippet: Fig. 4. A Rab6A-dependent immunosuppressive secretory process. (A) Correlation of Rab6A mRNA levels with percentages of total CD8+ T cells (A, Left) and exhausted CD8+ T cells (A, Right) quantified by flow cytometric analysis in a human LUAD cohort. (B) Flow cytometric analysis of Rab6A-deficient (shRab6A#3 and #4) or replete (shCTL) 344SQ flank tumors isolated from syngeneic, immunocompetent mice (n = 6 tumors per cohort). Percentages of T cells (CD8+ T cells, CD44low/CD62Lhigh naive CD8+ T cells, PD1+/TIM3+ exhausted CD8+ T cells and CD44high/CD62Llow effector/memory CD8+ T cells) and antigen-presenting cells (dendritic cells, total macrophages, M1 macrophages, and M2 macrophages) were quantified. (C and D) Flank tumor weight and lung metastasis numbers in syngeneic, immunocompetent mice (dots) injected with Rab6A-deficient (shRab6A#3 and #4) or replete (shCTL) 344SQ cells and treated with IgG CTL or anti- CD8 (C) or anti-CD80/CD86 antibodies (D). Fold-changes in tumor size and lung metastasis numbers were calculated for each cohort based on the mean values in anti-CD8-, anti-CD80/86, and IgG-treated groups. (E) Subcutaneous tumor growth curves in syngeneic, immunocompetent mice (dots). Cohorts are color- coded. Mean ± SEM. ***P < 0.0005. (F) CD8-, granzyme B-, CD11c-, and F4/80-positive cells in flank tumors generated by injection of 344SQ cells into syngeneic, immunocompetent mice. The percentage of positive cells in each cohort (plot). (G) Schematic illustration of a working model. ZEB1 relieves Rab6A, Rab8A, and their associated GEFs from miR-148a-dependent silencing, thereby accelerating Rab6A- and Rab8A-dependent exocytotic trafficking of vesicles carrying cargos that enhance FA turnover (e.g., MMP14) and establish an immunosuppressive TME (e.g., cytokines and ATX) to promote cancer metastasis.

Article Snippet: For CD80/86 blockade, 300 μg of anti- CD80 (#BE0024, BioXCell) and 300 μg of anti- CD86 (#BE0025, BioXCell) per mouse were intraperitoneally administered 1 wk before tumor cell injection and then once a week to maintain the blockade as previously described (51).

Techniques: Isolation, Injection, Generated